Biotechnology
Medical
Biopharmaceutical

CymaBay Therapeutics

$6.22
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.21 (-3.27%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell CBAY and other stocks, options, ETFs, and crypto commission-free!

About CBAY

CymaBay Therapeutics Inc. Common Stock, also called CymaBay Therapeutics, is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Read More Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Employees
43
Headquarters
Newark, California
Founded
1988
Market Cap
427.28M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
714.52K
High Today
$6.44
Low Today
$6.18
Open Price
$6.44
Volume
471.78K
52 Week High
$14.00
52 Week Low
$4.82

Collections

Biotechnology
Medical
Biopharmaceutical
Therapy
Research And Development
Health
Pharmaceutical
Technology

CBAY Earnings

-$0.37
-$0.28
-$0.20
-$0.11
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.